Abstract: Small cell lung cancer (SCLC) is characterized by high malignancy and invasiveness. It is difficult to treat and has poor prognosis. The development of personalized and comprehensive treatment strategies through a multidisciplinary team (MDT) can effectively improve the survival and quality of life of patients with SCLC. Surgery is of great value in patients with early stage. Concurrent chemoradiotherapy is the cornerstone treatment for limited-stage SCLC, and immune consolidation can further improve the survival. Immunotherapy combined with chemotherapy has led to significant breakthroughs in the treatment of extensive-stage SCLC. With the advancement of radiotherapy technology and the development of antineoplastic agents, novel radiotherapy strategies and drug treatment schemes are being explored and optimized. Notably, several problems and challenges still remain. This article aimed to review the progress and strategies for the multidisciplinary treatment of SCLC.